NCT01381887 - A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.

DRUG

Canagliflozin 300mg/Placebo

"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."

DRUG

Canagliflozin 300mg/Canagliflozin 150mg

"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."

DRUG

Canagliflozin 300mg

Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.

Trial Locations (5)

Unknown

Chula Vista

Miramar

Cincinnati

Dallas

San Antonio

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY